Archives     Advertise     Editorial Calendar      Advertiser Index     Subscribe     Contact Us    


Hospitals And Pharmacists File Lawsuit Over Drug Companies' Refusals Of 340B Discounts


 

Five national hospital organizations and an organization of hospital pharmacists representing participants in the 340B drug pricing program filed a federal lawsuit today against the U.S. Department of Health and Human Services (HHS) over the department's failure to enforce program requirements and halt drug company actions that undermine the program. The groups are joined in the lawsuit by three 340B hospitals serving patient communities in need that have been harmed by the companies' refusals to provide discounts on prescription drugs dispensed at community-based pharmacies, as required by the 340B program.

The American Hospital Association (AHA), 340B Health, the American Society of Health-System Pharmacists (ASHP), America's Essential Hospitals (AEH), the Association of American Medical Colleges (AAMC), and the Children's Hospital Association (CHA) filed the lawsuit in the U.S. District Court for the Northern District of California. Avera St. Mary's Hospital in Pierre, S.D., Riverside Regional Medical Center in Newport News, Va., and St. Mary's Medical Center in San Francisco are the individual hospital plaintiffs in the lawsuit.

340B requires drug companies to offer discounts on outpatient drugs to hospitals and other providers that serve patient communities in need, including those in rural areas. These savings enable hospitals to provide more comprehensive health care and support to patients - including free or low-cost drugs - without incurring costs for taxpayers.

Since July, however, a growing number of drug companies have unilaterally refused to provide discounts to 340B hospitals on drugs that are dispensed at community-based pharmacies. Many hospitals, including the three named as plaintiffs, rely on these 340B savings because they enable them to continue providing crucial care to patients in need.

Despite frequent communications with HHS urging it to enforce the law and block these actions, the department has yet to do so. The 340B law does not permit drug companies to condition discounts on the locations where patients obtain these drugs.

The lawsuit asks the court to order that HHS require these drug companies to provide 340B discounts on the drugs dispensed at community-based pharmacies and issue refunds to hospitals that were refused discounts. It also asks for an order requiring HHS to refer the drug companies responsible for these violations to the HHS Office of Inspector General (OIG) to assess penalties the law requires.

"The 340B program plays a critical role in helping eligible hospitals provide a wide range of comprehensive services and low-cost drugs to vulnerable patients and communities, many of which have been the hardest hit by the COVID-19 pandemic," said Rick Pollack, AHA's president and CEO. "This lawsuit will require the department to take actions that we've long called for against drug companies that are disregarding the law by limiting the distribution of certain 340B drugs to eligible hospitals. It's time to stop these illegal actions from drug companies and protect vulnerable patients and communities."

"The federal government has the responsibility to enforce the law by requiring that drug manufacturers offer discounts on covered drugs to eligible 340B hospitals," said Maureen Testoni, 340B Health's president and CEO. "These hospitals provide 60% of all uncompensated care in the U.S. and 75% of all hospital care to Medicaid patients. Our joint lawsuit demonstrates the immense harm this issue has caused the nation's 340B hospitals and the low-income and rural patients who rely on them for care, and it makes a strong case for the court to intervene now before the damage to the health care system becomes permanent."

"Hospital and health-system pharmacists have seen firsthand how critical the 340B program is in serving low-income patients in rural and urban areas throughout our country," said Paul W. Abramowitz, Pharm.D., Sc.D. (Hon.), FASHP, ASHP's CEO. "Our patients depend on this program, which ensures that our most vulnerable populations have access to the care they need. Now more than ever, as we navigate a public health emergency, it is essential that the program be implemented as Congress intended it."

"Drug industry players have moved without restraint to undermine the 340B drug pricing program, putting access to vital medications at risk for millions of Americans and destabilizing hospitals - including those on the front lines of the COVID-19 pandemic," said Bruce Siegel, MD, MPH, AEH's president and CEO. "We are asking the court to do what federal officials so far have failed to do: stop these unlawful actions and protect the nation's safety net."

"At no cost to the federal government, the 340B drug pricing program allows safety-net providers, many of which are teaching hospitals, to deliver critical health care services to low-income and vulnerable patients. This includes providing free or substantially discounted drugs to low-income patients, establishing neighborhood clinics, and improving access to specialized care previously unavailable in some areas," said David J. Skorton, MD, AAMC's president and CEO. "The lack of action by HHS to enforce the current statute will hurt low-income, rural, and other underserved patients and communities who will no longer be able to access vital services."

"The 340B program makes it possible for children's hospitals to provide life-saving medications to children," said Amy Knight, CHA's president. "This critical program is essential to the health outcomes of many children, and the discounts on these pharmaceuticals enable children's hospitals to care for these children and continue to provide services to the broader communities we serve."

For more information, please read the complaint and the memo in support of a motion for a preliminary and permanent injunction.

 
Share:

Related Articles:


Recent Articles

AACR Establishes New Cancer Evolution Working Group

The American Association for Cancer Research (AACR) announced the formation of its seventh and newest scientific working group, which will be dedicated to supporting cancer evolution research.

Read More

Global Dementia Cases Forecasted To Triple By 2050

New analysis shows a decrease in prevalence due to education countered by increase due to heart health risk factors

Read More

Blackburn, Feinstein Introduce Bill to Protect Access to Breast Cancer Screenings

U.S. Senators Marsha Blackburn (R-Tenn.) and Dianne Feinstein (D-Calif.) today introduced the Protecting Access to Lifesaving Screenings (PALS) Act of 2021, a bill to preserve coverage for routine breast cancer screening for women beginning at age 40.

Read More

CUMBERLAND PHARMACEUTICALS REPORTS 2.5M PATIENT DOSES DELIVERED, NO PRODUCT RECALLS, NO FDA ISSUES IN 2020

The company's 2020 sustainability report highlights its commitment to environmental, social and governance (ESG) activities

Read More

Mobile Mentor Named Winner of Microsoft's 2021 Partner of the Year for Modern Endpoint Management

Mobile Mentor announced they have been awarded the 2021 Global Partner of the Year Award for Modern Endpoint Management.

Read More

Alzheimer's Association Welcomes CMS Announcement of National Coverage Determination Analysis on Treatment for Alzheimer's Disease

On behalf of all those living with Alzheimer's disease, their caregivers, and their families, we appreciate the Centers for Medicare & Medicaid Services (CMS) thoughtful consideration on coverage considerations for monoclonal antibodies targeting amyloid for the treatment of Alzheimer's disease, including aducanumab, which was recently approved by the Food and Drug Administration (FDA).

Read More

HCTec Acquires Talon Healthy IT Services

Healthcare IT firm adds industry-leading help desk service company to portfolio of solutions

Read More

The Seven Steps of Revenue Cycle for a Healthcare Practice

Revenue cycle management tracks patient revenue from the initial encounter with the healthcare system to payment of balance. Getting the seven steps of revenue cycle right helps providers avoid missteps that are costly to the bottom line.

Read More

Expanding Evidence-Based Care for Dementia

The Alzheimer's Association is on a mission to ensure care professionals have access to evidence-based training to ensure those with dementia receive quality care across all settings.

Read More

A Natural Leader

Nashville physician Dr. Ryan Mire to head nation's largest medical-specialty society.

Read More

Email Print
 
 

 

 


Tags:
None
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: